Company intelligence / Profile preview

Zhejiang Innovation Biotechnology

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Zhejiang Innovation Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative therapies for metabolic diseases and endocrine disorders. The company focuses on next-generation treatments for conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Its lead programs include multi-receptor agonists targeting GLP-1, GIP, and Glucagon pathways to provide superior glycemic control and weight loss. Zhejiang Innovation Biotechnology leverages its expertise in peptide and small molecule chemistry to advance a robust pipeline of metabolic drug candidates.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Zhejiang Innovation Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Innovation Biotechnology.

Explore the full profile